Membranous nephropathy, leiomyoma and autoimmune myasthenia: more than a coincidence?

Membranous nephropathy (MN) has been associated with several infectious, immunological and malignant conditions, but had only rarely been reported with malignant and other immune disorders in the same patient. We describe the case of a 56-year-old male with MN who was also diagnosed with a gastrointestinal stromal tumour (GIST), myasthenia gravis (MG) and thymic hyperplasia. Thus, we report here for the first time the coincidence of these conditions in the same patient. There was a recurrence of nephrotic syndrome without impairment of renal function 5 years after removal of the GIST (3 years after thymectomy). The possible basis for the relationship between these diseases is discussed, and some common genetic and immune physiopathological pathways are hypothesized.

[1]  Z. Argov,et al.  Myasthenia gravis appearing 18years after resection of benign thymoma with subsequent limbic encephalitis , 2012, Journal of the Neurological Sciences.

[2]  D. Pinkel,et al.  Genome-wide copy number analysis of circulating tumor cells from patients (pts) with metastatic breast cancer (MBC). , 2011, Journal of Clinical Oncology.

[3]  L. Beck.  Membranous nephropathy and malignancy. , 2010, Seminars in nephrology.

[4]  A. Gomez,et al.  Antibody effector mechanisms in myasthenia gravis—Pathogenesis at the neuromuscular junction , 2010, Autoimmunity.

[5]  E. Beghi,et al.  Risk factors for tumor occurrence in patients with myasthenia gravis , 2009, Journal of Neurology.

[6]  V. Bijol,et al.  Membranous nephropathy associated with gastrointestinal stromal tumour: a case report , 2009, NDT plus.

[7]  R. Vilallonga,et al.  A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis , 2009 .

[8]  R. Hohlfeld,et al.  Reflections on the “intrathymic pathogenesis” of myasthenia gravis , 2008, Journal of Neuroimmunology.

[9]  刘双信,et al.  Membranous nephropathy , 2008 .

[10]  Shigeaki Suzuki,et al.  Classification of myasthenia gravis based on autoantibody status. , 2007, Archives of neurology.

[11]  G. Remuzzi,et al.  Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. , 2006, Kidney international.

[12]  A. Rolink,et al.  Critical role for c‐kit (CD117) in T cell lineage commitment and early thymocyte development in vitro , 2006, European journal of immunology.

[13]  R. DeMatteo,et al.  Gastrointestinal stromal tumor: 5 years later , 2005, Cancer.

[14]  M. Heinrich,et al.  PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Grünfeld,et al.  Renal and thymic pathology in thymoma-associated nephropathy: report of 21 cases and review of the literature. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[16]  A. Komatsuda,et al.  Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[17]  M. Matsuda,et al.  Myasthenia gravis with membranous nephropathy, successfully treated with extended total thymectomy. , 2000, Internal medicine.

[18]  G. Fogazzi,et al.  Glomerulonephritis associated with myasthenia gravis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[19]  G. Hughes,et al.  Appearance of systemic lupus erythematosus after thymectomy: four case reports and review of the literature , 1995, Lupus.

[20]  D. Elmqvist.  Myasthenia Gravis , 1975, The Lancet.

[21]  A. Cybulsky.  Membranous nephropathy. , 2011, Contributions to nephrology.

[22]  S. Hirota,et al.  Good clinical response to imatinib mesylate in atypical thymic carcinoid With KIT overexpression. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Ziegler,et al.  Imatinib suppresses cryoglobulinemia and secondary membranoproliferative glomerulonephritis. , 2009, Journal of the American Society of Nephrology : JASN.

[24]  C. Alpers,et al.  A new look at platelet-derived growth factor in renal disease. , 2008, Journal of the American Society of Nephrology : JASN.